PDL BioPharma Dividend Yield: 9.20%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PDLI Dividend Yield Rankings
| Overall | 98th percentile | 90 of 4678 |
| Sector | 99th percentile | 2 of 531 in Healthcare |
| Industry | 99th percentile | 1 of 165 in Biotechnology |
PDLI Dividend Yield Range, Past 5 Years
| Minimum | 0.00% | Mar 1999 |
| Maximum | 0.00% | Mar 1999 |
| Average |
About Dividend Yield
The dividend yield is the sum company's annual dividends per share, divided by the current price per share. It is often expressed as a percentage. It the reciprocal of the price/dividend ratio. By investing in a company with a high dividend yield, investors can secure a relatively stable cash flow. However, it is important to note that sometimes dividend yields are high when a company is facing financial trouble, and the company may cut the dividend in the near future.
For example, if a stock trades at $36 and pays $1.80 in dividends over the course of one year ($.45 per quarter), the company's dividend yield is 5%.
Learn More
You may also be interested in these PDLI related companies
PDLI News
Seth Klarman's Baupost Group drastically reduces PDL BioPharma $PDLI position http://stks.co/2LmR
about 2 days ago by marketfolly
about 2 days ago by marketfolly
PDL BioPharma to Present at the 14th Annual BIO CEO & Investor Conference
Feb 07, 7:00AM PR Newswire
Feb 07, 7:00AM PR Newswire
PDL BioPharma Announces Exchange of Its 2.875% Convertible Senior Notes due February 15, 2015
Feb 02, 5:08PM Benzinga
Feb 02, 5:08PM Benzinga
PDL BioPharma, Inc. (PDLI) Declares $0.15 September Quarterly Dividend; 9.4% Yield
Jan 24, 7:12AM Street Insider
Jan 24, 7:12AM Street Insider
PDL BioPharma, Inc. (PDLI) Declares $0.15 Quarterly June Dividend; 9.4% Yield
Jan 24, 7:11AM Street Insider
Jan 24, 7:11AM Street Insider
PDL BioPharma, Inc. (PDLI) Declares $0.15 Quarterly Dividend; 9.4% Yield
Jan 24, 7:09AM Street Insider
Jan 24, 7:09AM Street Insider
PDL BioPharma's CEO Presents at 30th Annual JP Morgan Healthcare Conference (Transcript)
Jan 12, 6:49PM Seeking Alpha
Jan 12, 6:49PM Seeking Alpha
PDL BioPharma Announces Settlement and Final Results of its Exchange Offer
Jan 05, 8:03PM PR Newswire
Jan 05, 8:03PM PR Newswire
PDL BioPharma to Present at the 30th Annual JP Morgan Healthcare Conference
Jan 05, 7:00AM PR Newswire
Jan 05, 7:00AM PR Newswire
PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
Jan 03, 6:55PM PR Newswire
Jan 03, 6:55PM PR Newswire
Exclusive: Seth #Klarman’s Secret Holdings @ http://stks.co/1h07 http://stks.co/1h08 #debt #shorts $TRGT $BP $NWSA $CSE $HP $PDLI $MSFT $ERO
about 47 days ago by valuewalk
about 47 days ago by valuewalk
PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million
Dec 19, 7:00AM PR Newswire
Dec 19, 7:00AM PR Newswire
12 breakouts. $HMSY, $PDLI (stop: $5.72). One penny stock. Two between $1-2. Number of breakouts okay but individual stocks so-so.
about 97 days ago by fallondpicks
about 97 days ago by fallondpicks
Sweet mother of god what have I done confused $PDLI w $NPSP damn bio tech initials, no one has the imagination for snappy names, apologies
about 101 days ago by zimmy818
about 101 days ago by zimmy818
@harmongreg of course $PDLI held up great bogus press shook a lot of investors out, including me, probably a great call hope you hit your #s
about 101 days ago by zimmy818
about 101 days ago by zimmy818
$PDLI talk about panic caused by an ass wipe of an analyst (shook me out) lung cancer isn't related to your colon after all,
about 101 days ago by zimmy818
about 101 days ago by zimmy818
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PDLI | 6.39 | -0.10 | -1.54% | 893.26M |
| HSNI | 35.34 | -0.35 | -0.98% | 2.08B |
| MSFT | 30.50 | -0.28 | -0.89% | 256.53B |
| MXIM | 27.19 | -0.57 | -2.05% | 7.93B |
| GOOG | 605.91 | -5.55 | -0.91% | 196.25B |
| BPOP | 1.68 | -0.09 | -5.08% | 1.72B |
| VECO | 28.36 | 0.08 | 0.28% | 1.10B |
| ATPG | 6.69 | -0.14 | -2.05% | 345.34M |
| C | 32.92 | -0.73 | -2.18% | 96.26B |
| BEST | 0.62 | -0.11 | -15.07% | 17.07M |
